A prospective randomized trial examining health care utilization in individuals using multiple smartphone-enabled biosensors

被引:62
作者
Bloss, Cinnamon S. [1 ]
Wineinger, Nathan E. [1 ]
Peters, Melissa [1 ]
Boeldt, Debra L. [1 ]
Ariniello, Lauren [1 ]
Kim, Ju Young [2 ]
Sheard, Judith [1 ]
Komatireddy, Ravi [1 ]
Barrett, Paddy [1 ]
Topol, Eric J. [1 ,3 ,4 ]
机构
[1] Scripps Translat Sci Inst, La Jolla, CA 92037 USA
[2] Seoul Natl Univ, Bundang Hosp, Dept Family Med, Seoul, South Korea
[3] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA
[4] Scripps Hlth, Div Cardiovasc Dis, San Diego, CA USA
来源
PEERJ | 2016年 / 4卷
关键词
Digital medicine; Mobile health; Health insurance claims; Health monitoring; Hypertension; Arrhythmia; Diabetes; ATRIAL-FIBRILLATION; BLOOD-PRESSURE; HYPERTENSION; DIAGNOSIS; FORM;
D O I
10.7717/peerj.1554
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background. Mobile health and digital medicine technologies are becoming increasingly used by individuals with common, chronic diseases to monitor their health. Numerous devices, sensors, and apps are available to patients and consumers-some of which have been shown to lead to improved health management and health outcomes. However, no randomized controlled trials have been conducted which examine health care costs, and most have failed to provide study participants with a truly comprehensive monitoring system. Methods. We conducted a prospective randomized controlled trial of adults who had submitted a 2012 health insurance claim associated with hypertension, diabetes, and/or cardiac arrhythmia. The intervention involved receipt of one or more mobile devices that corresponded to their condition(s) (hypertension: Withings Blood Pressure Monitor; diabetes: Sanofi iBGStar Blood Glucose Meter; arrhythmia: AliveCor Mobile ECG) and an iPhone with linked tracking applications for a period of 6 months; the control group received a standard disease management program. Moreover, intervention study participants received access to an online health management system which provided participants detailed device tracking information over the course of the study. This was a monitoring system designed by leveraging collaborations with device manufacturers, a connected health leader, health care provider, and employee wellness program-making it both unique and inclusive. We hypothesized that health resource utilization with respect to health insurance claims may be influenced by the monitoring intervention. We also examined health-self management. Results & Conclusions. There was little evidence of differences in health care costs or utilization as a result of the intervention. Furthermore, we found evidence that the control and intervention groups were equivalent with respect to most health care utilization outcomes. This result suggests there are not large short-term increases or decreases in health care costs or utilization associated with monitoring chronic health conditions using mobile health or digital medicine technologies. Among secondary outcomes there was some evidence of improvement in health self-management which was characterized by a decrease in the propensity to view health status as due to chance factors in the intervention group.
引用
收藏
页数:16
相关论文
共 24 条
[1]   Economic Costs of Diabetes in the U.S. in 2012 [J].
Yang W. ;
Dall T.M. ;
Halder P. ;
Gallo P. ;
Kowal S.L. ;
Hogan P.F. ;
Petersen M. .
DIABETES CARE, 2013, 36 (04) :1033-1046
[2]  
[Anonymous], 2014, NATL DIABETES STAT R, P2009
[3]   How Consumers and Physicians View New Medical Technology: Comparative Survey [J].
Boeldt, Debra L. ;
Wineinger, Nathan E. ;
Waalen, Jill ;
Gollamudi, Shreya ;
Grossberg, Adam ;
Steinhubl, Steven R. ;
McCollister-Slipp, Anna ;
Rogers, Marc A. ;
Silvers, Carey ;
Topol, Eric J. .
JOURNAL OF MEDICAL INTERNET RESEARCH, 2015, 17 (09) :e215
[4]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[5]  
Davis K.E., 2013, Expenditures for hypertension among adults age 18 and older, 2010: Estimates for the US civilian noninstitutionalized population
[6]   Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure [J].
Ernst, ME ;
Carter, BL ;
Goerdt, CJ ;
Steffensmeier, JJG ;
Phillips, BB ;
Zimmerman, MB ;
Bergus, GR .
HYPERTENSION, 2006, 47 (03) :352-358
[7]  
Free C, 2013, PLOS MED, V10, DOI [10.1371/journal.pmed.1001363, 10.1371/journal.pmed.1001362]
[8]  
Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967
[9]  
Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981
[10]   DETERMINING OPTIMAL THERAPY - RANDOMIZED TRIALS IN INDIVIDUAL PATIENTS [J].
GUYATT, G ;
SACKETT, D ;
TAYLOR, DW ;
CHONG, J ;
ROBERTS, R ;
PUGSLEY, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (14) :889-892